News

December 6, 2023

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

November 13, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

November 7, 2023

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

November 2, 2023

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

October 25, 2023

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

October 17, 2023

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

October 13, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

October 10, 2023

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

September 22, 2023

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

September 19, 2023

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity